Market Cap: $293.13B
Market Cap: $293.13B

Novartis AG ( NVS ) continues to establish itself as a leader in the pharmaceutical industry, particularly as it navigates the challenges and opportunities surrounding patent expirations and changing…

Novartis AG (Ticker: NVS) continues to position itself as a key player in the fight against Facioscapulohumeral Muscular Dystrophy (FSHD), a debilitating genetic condition that affects tens of thousan…
Novartis Drives Forward with Strategic Acquisition for Allergy Treatments Swiss pharmaceutical giant Novartis is poised to enhance its portfolio in allergy treatments through the acquisition of U.S.-b…
Novartis Expands Reach with FDA Approval of Cosentyx for Pediatric Use In a significant development for pediatric care in autoimmune disorders, Novartis AG secures U.S. Food and Drug Administration (F…
Novartis Expands Pediatric Treatment Options with FDA Approval of Cosentyx Novartis AG announces a major advancement in pediatric healthcare with the recent FDA approval of its anti-inflammatory drug,…
Novartis AG Secures FDA Approval for Cosentyx in Pediatric Patients In a significant milestone for pediatric healthcare, the U.S. Food and Drug Administration (FDA) recently approves Novartis AG's Cos…
### Oncology Market Dynamics Highlighted by Roche’s Breast Cancer Study In recent developments within the oncology sector, Roche Holdings AG releases promising data from its phase 3 persevERA Breast C…
Roche's Clinical Trial Impacts Competitive Landscape in Oncology Roche Holdings AG's recent Phase 3 clinical trial results for giredestrant in combination with palbociclib have significant implication…
Novartis AG: Navigating the Landscape of Oncology Trials amid Competitive Pressures In the fast-paced world of oncology, Novartis AG finds itself at the forefront of therapeutic innovation, competing…
Growing Short Interest Reflects Market Sentiments for Novartis AG The recent spike in short interest for Novartis AG (NYSE:NVS) highlights a notable shift in the perceptions of market traders regardin…
Novartis Steps Toward Ethical Reform with Henrietta Lacks Settlement In a notable advancement for ethical considerations in medical research, Novartis AG has reached a confidential settlement with the…
### A Landmark Settlement for Ethical Considerations in Medical Research Novartis AG has reached a confidential settlement with the family of Henrietta Lacks, marking a significant milestone decades a…
Novartis Reaches Confidential Settlement with Henrietta Lacks Family, Signaling Ethical Shift in Pharmaceutical Research In a significant development for the pharmaceutical industry, Novartis AG has f…
Novartis sees pipeline and regulatory milestones climb to centre stage Novartis AG is facing heightened scrutiny over its drug pipeline and upcoming regulatory milestones as analysts and investors shi…
Novartis narrows focus on clinical and regulatory milestones as market attention intensifies BASEL, Switzerland — Novartis AG is placing its pharmaceutical pipeline and impending regulatory milestones…
Novartis among drugmakers tied to White House TrumpRx rollout Novartis is named by the White House as one of several major pharmaceutical companies committing to participate in a new federal initiativ…
Policy wave tests pharma strategy A provision in the recent U.S. government funding bill aimed at lowering drug prices is forcing multinational drugmakers such as Novartis AG to reassess their U.S. co…
Supply Lines Under the Microscope: Washington minerals summit alarms drugmakers Main Topic — Novartis and the race for pharmaceutical-grade minerals The U.S. State Department is hosting miners from ab…
U.S. funding bill pushes drugmakers to rethink pricing and product strategy A provision in the recent U.S. government funding bill aimed at lowering prescription drug costs is driving fresh strategic…
Market volatility tests pharma supply chains Global market risk-off sentiment and falling commodity prices are reshaping cost and logistics dynamics for large drugmakers such as Novartis AG. As oil, g…
Policy push forces pharma to reassess U.S. strategy Drug-pricing language in a recent U.S. government funding bill is prompting multinational drugmakers, including Novartis AG, to recalibrate commerci…
Novartis AG: Embracing AI for Enhanced Diagnostics in Oncology In a rapidly evolving healthcare landscape, Novartis AG stands to benefit from the growing trend of artificial intelligence (AI) applicat…
Novartis Resilience Amidst Tariff Threats: A Strategic Shield Swiss pharmaceutical giant Novartis AG, under the leadership of CEO Vas Narasimhan, demonstrates a robust strategy to mitigate the impact…
Navigating Trade Challenges: Novartis' Strategic Response to U.S. Tariffs At the World Economic Forum in Davos, Novartis AG's CEO Vas Narasimhan articulates the company's robust strategy to mitigate t…
Novartis Embraces AI in Drug Development: A New Era for Pharmaceuticals Novartis AG is at the forefront of integrating artificial intelligence (AI) into its drug development processes, an initiative h…
Innovative Horizons: Novartis Explores AI in Drug Development At the forefront of pharmaceutical innovation, Novartis AG’s CEO, Dr. Vasant Narasimhan, emphasizes the transformative potential of artifi…
Novartis Partners with SciNeuro to Advance Alzheimer's Treatment In a groundbreaking collaboration, Novartis Pharma AG secures an exclusive worldwide license from SciNeuro Pharmaceuticals to develop a…
Novartis and SciNeuro Join Forces to Combat Alzheimer's Disease In a groundbreaking collaboration, Novartis Pharma AG secures an exclusive worldwide license from SciNeuro Pharmaceuticals for the devel…
Novartis AG Focuses on Innovative Therapeutics Amid Industry Shifts In a rapidly evolving pharmaceutical landscape, Novartis AG remains committed to advancing its pipeline of innovative therapeutics,…
Novartis Leads the Charge in Social Impact and Sustainability In the latest edition of BizClik's Sustainability portfolio, Novartis AG stands out with a cover feature that underscores its commitment t…
Novartis AG: Advancing Autoimmune Disorder Treatments Amidst Industry Innovations In the evolving landscape of autoimmune disorder treatments, Novartis AG finds itself in a pivotal position, particula…
Novartis AG's Commitment to Social Impact Through Sustainability Initiatives In the latest edition of BizClik's Sustainability portfolio, Novartis AG stands out for its commitment to social impact, pa…
Novartis AG: Advancing Social Impact Through Sustainability Initiatives In recent days, Novartis AG gains recognition for its commitment to social impact as highlighted in the January 2026 edition of…
Rising Drug Prices: A Growing Concern for Patients and Healthcare Advocates The pharmaceutical industry faces intensified scrutiny as drug manufacturers announce plans to increase prices on over 350 b…
Pharmaceutical Pricing Pressures: A Growing Concern for Novartis AG In the face of increasing scrutiny over drug pricing, Novartis AG and other pharmaceutical manufacturers are poised to raise prices…
Pharmaceutical Pricing Strategies Under Scrutiny: Implications for Patients and Public Health In a significant development for the pharmaceutical industry, over 350 branded medications, including crit…
Roche CEO Warns of Global Drug Pricing Impact from U.S. Policy Changes Thomas Schinecker, CEO of Roche Holding AG, raises critical concerns regarding the recent agreements between pharmaceutical compa…
Novartis and the Push for Affordable Medications: A New Era in Drug Pricing In a bold move to address the persistent issue of high prescription drug costs in the United States, President Donald Trump…
Novartis AG: Navigating New Drug Pricing Agreements Amid U.S. Policy Changes In a significant move to tackle the high cost of prescription drugs, President Donald Trump announces agreements with nine…
Roche's Breakthrough in Breast Cancer Treatment: A Game Changer for Oncology Roche Holdings AG announces promising interim results from its phase 3 lidERA Breast Cancer study, which evaluates an inves…
Novartis AG Advances Treatment for Immune Thrombocytopenia with VAYHIT2 Trial Results Novartis AG (NYSE:NVS) announces significant findings from its VAYHIT2 Phase 3 trial, which evaluates the efficacy…
Novartis AG Advances Treatment for Primary Immune Thrombocytopenia with VAYHIT2 Phase 3 Trial Results Novartis AG announces promising results from the VAYHIT2 Phase 3 trial, which evaluates the effica…
Novartis AG Advances Treatment for Primary Immune Thrombocytopenia with VAYHIT2 Trial Results Novartis AG has made significant strides in the management of primary immune thrombocytopenia (ITP) with t…
Novartis AG Advances in Innovative Drug Development Amid Market Optimism In the rapidly evolving pharmaceutical landscape, Novartis AG finds itself at the forefront of innovative drug development, foc…
Novartis AG Advances in Innovative Drug Development Amid Market Optimism Novartis AG remains at the forefront of the pharmaceutical industry, currently making significant strides in its innovative dru…
Arrowhead Pharmaceuticals Sets High Bar with Strong Q4 Performance Arrowhead Pharmaceuticals, Inc. announces impressive fourth-quarter financial results that exceed market expectations, marking a sign…
Novartis Advances SMA Treatment with Itvisma Approval Novartis AG achieves a transformative milestone with the FDA's approval of Itvisma® (onasemnogene abeparvovec-brve), marking the first gene replac…
Novartis AG’s Transformational Gene Therapy Receives FDA Approval for SMA Treatment Novartis AG achieves a significant milestone with the recent FDA approval of its gene therapy product, Itvisma® (ona…
Novartis AG Charts a Path of Innovation and Growth Through 2030 Novartis AG is poised for significant advancement in the pharmaceutical sector, projecting a robust growth trajectory through 2030. The…
Harnessing AI for Transformative Healthcare Solutions: Novartis AG's Strategic Vision In the rapidly evolving landscape of the pharmaceutical industry, Novartis AG stands at the forefront of a transfo…